Illumina Deploys Clinical Whole-Genome Sequencing for Rare Disease Testing at FSU Lab
Illumina Laboratory Services will provide clinical whole-genome sequencing and interpretation to the new Diagnostic Lab at Florida Institute for Pediatric Rare Diseases at FSU College of Medicine, aiming to accelerate rare disease diagnostics. The service supports faster identification of novel mutations to reduce time from diagnosis to clinical management.
1. Partnership Launch with FSU Diagnostic Lab
Illumina Laboratory Services is now providing clinical whole-genome sequencing and interpretation services to the new Diagnostic Lab at the Florida Institute for Pediatric Rare Diseases at FSU College of Medicine, enabling advanced rare disease diagnostics.
2. Clinical Sequencing Impact and Goals
Clinical whole-genome sequencing adoption aims to accelerate identification of novel pathogenic mutations hidden in complex genomic regions, reducing diagnostic odyssey durations for pediatric patients and informing targeted clinical management more quickly.
3. Workflow Enablement and Implementation
Illumina’s Customer Success and Implementation team supported rapid workflow deployment, allowing the IPRD Diagnostic Lab to initiate testing without delays by adapting research protocols to meet CLIA-certified clinical standards.
4. Broader Implications for Rare Diseases
This collaboration builds on a long-term relationship with FSU and highlights Illumina’s commitment to expanding clinical sequencing services, potentially improving health outcomes for the millions of Americans living with rare genetic diseases.